![](/images/2013/post-sep.jpg)
Alicia Kali Nominated for Two International Startup of the Year Awards for Two Powerfully Disruptive Launches
Panacea's NeuroGen and AK.AI's TheSoulOf.AI Recognized for Excellence
Panacea's NeuroGen: A Non-Opioid Breakthrough
Panacea's NeuroGen, a cutting-edge non-opioid treatment, is at the forefront of regenerative biomedicine. This innovative therapy addresses the critical need for effective pain management without the risks associated with opioid use, and serves as best in class by being regenerative, offering a transformative solution for patients suffering from chronic pain and neurodegenerative conditions.
AK.AI's TheSoulOf.AI: Merging Biology and Technology
AK.AI's TheSoulOf.AI represents a monumental leap in artificial intelligence, merging biology and technology to overcome AI's core challenges in cognition, discernment, reasoning, and emotional regulation. This pioneering approach not only enhances AI's functional capabilities but also brings it closer to human-like understanding and interaction, setting new benchmarks for the industry.
A Legacy of Innovation and Excellence
Alicia Kali's dual nominations underscore her commitment to pushing the boundaries of science and technology. With over a dozen awards to her name, including an unprecedented three International Startup of the Year Awards and a nomination for a precursor to the Nobel Prize in 2019, Kali continues to be a driving force in her fields. Her induction into Who's Who in America in 2024 further cements her status as a leading figure in biotechnology and AI.
About Alicia Kali
Alicia Kali is an acclaimed inventor and biotechnologist, whose contributions have been recognized globally, she is known for her innovative contributions to regenerative biomedicine and AI cognition. Through her companies, Panacea and AK.AI, she is dedicated to improving human health and advancing the capabilities of artificial intelligence.
Jana Smith
Panacea
https://panaceabiomed.com/
![](https://pharmaceuticals.einnews.com/tracking/article.gif?aid=727668170§ion=einpresswire&a=f7uvxp7PchCKuYfq&i=V16kJixGDUuySH0U)
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.